MediciNova says SEANOBI-ALS expanded-access study of MN-166 reaches 200-patient enrollment targetPUBT·Jul 15 at 07:03 AMMNOV-0.75%4875
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patientsUnusual Whales·Jul 15 at 07:02 AM4875MNOV-0.75%
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma TreatmentUnusual Whales·Jun 8 at 07:02 AMMNOV-0.75%4875
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) | MNOV Stock NewsStockTitan·May 26 at 10:00 AM4875MNOV-0.75%
<![CDATA[Modern Communication Between FDA, Biotech, and Investors: Q&A with David Crean]]>Pharmexec·May 22 at 05:00 AM4875MNOV-0.75%
